Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: Tumor and microenvironment

References

• Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Medical Chirurgical Trnasaction 1832; 17: 68–114
   PubMedGoogle Scholar
• Wilks S. Cases of lardaceous disease and some allied affections, with remark. Guys Hsop Rep 1856; 17: 103–132
   Google Scholar
• Wilks S. Cases with enlargement of the lymphatic glands and spleen (or Hodking's disease), with remarks. Guy's Hosp Rep 1865; 11: 56–67
   Google Scholar
• Greenfield W S. Specimens illustrative of the pathology of lymphadenoma and leucocythemia. Trans Path Soc London 1878; 29: 272–304
   Google Scholar
• Langerhans T. Das milgne lymphosarkom (pseudoleukamie). Virchow's Archiv f path Anatomie 1872; 54: 509–537
   Google Scholar
• Reed D M. On the pathological changes in Hodgkin's disease, with special reference to its relation to tuberculosis. Johns Hopkins Hosp Rep 1902; 10: 133–196
   Google Scholar
• Sternberg C. Uber eine eigenartige unter dem Bilde der Psuedoleukamie verlaufende Tuberculose des lymphatische Apparates. Ztschr Heilk 1898; 19: 21–90
   Google Scholar
• Fox H. Remarks on the microscopical preparations made form some of the original tissue described by Thomas Hodgkin 1832. Ann Med Hist 1926; 370–374
   Google Scholar
• Kaplan H S. Hodgkin's disease: unfolding concepts concerning its nature, management and prognosis. Cancer 1980; 45: 2439–2474
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. [Review][296 refs]. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• E S Jaffe, Harris, N L, Stein, H, Vardiman, J. Tumours of Haematopoeitic and Lymphoid Tissues. Lyon, IARC Press. 2001
   Google Scholar
• Hummel M, Ziemann K, Lammert H, et al. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells [see comments]. New Engl J Med 1995; 333: 901–906
   PubMed Web of Science ®Google Scholar
• Marafioti T, Hummel M, Foss H D, et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000; 95: 1443–1450
   PubMed Web of Science ®Google Scholar
• Delabie J, Tierens A, Gavriil T, et al. Phenotype, genotype and clonality of Reed-Sternberg cells in nodular sclerosis Hodgkin's disease: results of a single-cell study. Br J Haematol 1996; 94: 198–205
   PubMed Web of Science ®Google Scholar
• Kanzler H, Kuppers R, Hansmann M L, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996; 184: 1495–1505
   PubMed Web of Science ®Google Scholar
• Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 1994; 91: 10962–10966
   PubMed Web of Science ®Google Scholar
• Diehl V, Stein H, Hummel M, Zollinger R, Connors J M. Hodgkin's Lymphoma: biology and treatment strategies for primary, refractory, and relapsed DISEASE. Hematology (Am Soc Hematol Educ Program) 2003; 225–247
   PubMedGoogle Scholar
• Krappmann D, Emmerich F, Kordes U, et al. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18: 943–953
   PubMed Web of Science ®Google Scholar
• Thomas R K, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma – molecular biology of Hodgkin and Reed–Sternberg cells. Lancet Oncol 2004; 5: 11–18
   PubMed Web of Science ®Google Scholar
• Re D, Hofmann A, Wolf J, Diehl V, Staratschek-Jox A. Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95. Exp Hematol 2000; 28: 31–35
   PubMed Web of Science ®Google Scholar
• Maggio E M, van den B A, de Jong D, Diepstra A, Poppema S. Low frequency of FAS mutations in Reed–Sternberg cells of Hodgkin's lymphoma. Am J Pathol 2003; 162: 29–35
   PubMed Web of Science ®Google Scholar
• Muschen M, Re D, Brauninger A, et al. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res 2000; 60: 5640–5643
   PubMed Web of Science ®Google Scholar
• Thomas R K, Kallenborn A, Wickenhauser C, et al. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol 2002; 160: 1521–1528
   PubMed Web of Science ®Google Scholar
• Dutton A, O'Neil J D, Milner A E, et al. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci USA 2004; 101: 6611–6616
   PubMed Web of Science ®Google Scholar
• Mathas S, Lietz A, Anagnostopoulos I, et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004; 199: 1041–1052
   PubMed Web of Science ®Google Scholar
• Kashkar H, Haefs C, Shin H, et al. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med 2003; 198: 341–347
   PubMed Web of Science ®Google Scholar
• Kim L H, Nadarajah V S, Peh S C, Poppema S. Expression of Bcl-2 family members and presence of Epstein-Barr virus in the regulation of cell growth and death in classical Hodgkin's lymphoma. Histopathology 2004; 44: 257–267
   PubMed Web of Science ®Google Scholar
• van Spronsen D J, Peh S C, Vrints L W, van Imhoff G W, Poppema S. Clinical drug-resistant nodular sclerosing Hodgkin's lymphoma is associated with decreased bcl-2 expression in the surrounding lymphocytes and with increased bcl-2 expression in the Reed-Sternberg cells. Histopathology 2000; 37: 420–426
   PubMed Web of Science ®Google Scholar
• Chu W S, Aguilera N S, Wei M Q, Abbondanzo S L. Antiapoptotic marker Bcl-X(L), expression on Reed-Sternberg cells of Hodgkin's disease using a novel monoclonal marker, YTH-2H12. Hum Pathol 1999; 30: 1065–1070
   PubMed Web of Science ®Google Scholar
• Hell K, Lorenzen J, Fischer R, Hansmann M L. Hodgkin cells accumulate mRNA for bcl-2. Lab Invest 1995; 73: 492–496
   PubMed Web of Science ®Google Scholar
• Sup S J, Alemany C A, Pohlman B, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol 2005; 23: 3773–3779
   PubMed Web of Science ®Google Scholar
• Kucharczak J, Simmons M J, Fan Y, Gelinas C. To be, or not to be: NF-kappaB is the answer–role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003; 22: 8961–8982
   PubMed Web of Science ®Google Scholar
• Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18: 6938–6947
   PubMed Web of Science ®Google Scholar
• Bargou R C, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961–2969
   PubMed Web of Science ®Google Scholar
• Hinz M, Loser P, Mathas S, et al. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001; 97: 2798–2807
   PubMed Web of Science ®Google Scholar
• Izban K F, Ergin M, Huang Q, et al. Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol 2001; 14: 297–310
   PubMed Web of Science ®Google Scholar
• Zhao X, Qiu W, Kung J, et al. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: A gene expression profiling study with implications for potential combination therapies. Leuk Res 2007
   Web of Science ®Google Scholar
• Carbone A, Gloghini A, Gruss H J, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 1995; 147: 912–922
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780–789
   PubMed Web of Science ®Google Scholar
• Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999; 94: 3129–3134
   PubMed Web of Science ®Google Scholar
• Fiumara P, Snell V, Li Y, et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 2001; 98: 2784–2790
   PubMed Web of Science ®Google Scholar
• Cabannes E, Khan G, Aillet F, Jarrett R F, Hay R T. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 1999; 18: 3063–3070
   PubMed Web of Science ®Google Scholar
• Wood K M, Roff M, Hay R T. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene 1998; 16: 2131–2139
   PubMed Web of Science ®Google Scholar
• Herbst H. Epstein-Barr virus in Hodgkin's disease. Semin Cancer Biol 1996; 7: 183–189
   PubMed Web of Science ®Google Scholar
• Bechtel D, Kurth J, Unkel C, Kuppers R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood 2005; 106: 4345–4350
   PubMed Web of Science ®Google Scholar
• Chaganti S, Bell A I, Pastor N B, et al. Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood 2005; 106: 4249–4252
   PubMed Web of Science ®Google Scholar
• Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of “crippled” germinal center B cells from apoptosis by Epstein-Barr virus. Blood 2005; 106: 4339–4344
   PubMed Web of Science ®Google Scholar
• Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J 1997; 16: 6131–6140
   PubMed Web of Science ®Google Scholar
• Caldwell R G, Wilson J B, Anderson S J, Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998; 9: 405–411
   PubMedGoogle Scholar
• Maggio E, van den B A, Diepstra A, et al. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002; 13(Suppl 1)52–56
   PubMed Web of Science ®Google Scholar
• Poppema S. Immunobiology and pathophysiology of hodgkin lymphomas. Hematology (Am Soc Hematol Educ Program) 2005; 231–238
   PubMedGoogle Scholar
• Chiu A, Xu W, He B, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007; 109: 729–739
   PubMed Web of Science ®Google Scholar
• Hanamoto H, Nakayama T, Miyazato H, et al. Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol 2004; 164: 997–1006
   PubMed Web of Science ®Google Scholar
• Skinnider B F, Mak T W. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99: 4283–4297
   PubMed Web of Science ®Google Scholar
• Skinnider B F, Kapp U, Mak T W. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 2002; 43: 1203–1210
   PubMed Web of Science ®Google Scholar
• Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007; 104: 13134–13139
   PubMed Web of Science ®Google Scholar
• Jundt F, Anagnostopoulos I, Bommert K, et al. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999; 94: 2065–2071
   PubMed Web of Science ®Google Scholar
• Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008; 111: 3220–3224
   PubMed Web of Science ®Google Scholar
• Fischer M, Juremalm M, Olsson N, et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003; 107: 197–201
   PubMed Web of Science ®Google Scholar
• Glimelius I, Edstrom A, Amini R M, et al. IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. Eur J Haematol 2006; 76: 278–283
   PubMed Web of Science ®Google Scholar
• Molin D, Fischer M, Xiang Z, et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 2001; 114: 616–623
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease N Engl J Med 1998; 339: 1506–1514
   Google Scholar
• Casasnovas R O, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 1732–1740
   PubMed Web of Science ®Google Scholar
• Gause A, Pohl C, Tschiersch A, et al. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 1991; 77: 1983–1988
   PubMed Web of Science ®Google Scholar
• Gause A, Jung W, Schmits R, et al. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma. Ann Oncol 1992; 3(Suppl 4)49–52
   PubMedGoogle Scholar
• Gause A, Jung W, Keymis S, et al. The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin's disease. Leuk Lymphoma 1992; 7: 439–447
   PubMed Web of Science ®Google Scholar
• Nadali G, Vinante F, Ambrosetti A, et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 1994; 12: 793–797
   PubMed Web of Science ®Google Scholar
• Visco C, Nadali G, Vassilakopoulos T P, et al. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol 2006; 77: 387–394
   PubMed Web of Science ®Google Scholar
• Zanotti R, Trolese A, Ambrosetti A, et al. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol 2002; 13: 1908–1914
   PubMed Web of Science ®Google Scholar
• Axdorph U, Sjoberg J, Grimfors G, et al. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. Ann Oncol 2000; 11: 1405–1411
   PubMed Web of Science ®Google Scholar
• Herbst H, Foss H D, Samol J, et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996; 87: 2918–2929
   PubMed Web of Science ®Google Scholar
• Marshall N A, Christie L E, Munro L R, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755–1762
   PubMed Web of Science ®Google Scholar
• Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol 2000; 79: 110–113
   PubMed Web of Science ®Google Scholar
• Salgami E V, Efstathiou S P, Vlachakis V, et al. High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma. Haematologia (Budap) 2002; 32: 377–387
   PubMedGoogle Scholar
• Sarris A H, Kliche K O, Pethambaram P, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999; 10: 433–440
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos T P, Nadali G, Angelopoulou M K, et al. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica 2001; 86: 274–281
   PubMed Web of Science ®Google Scholar
• Visco C, Vassilakopoulos T P, Kliche K O, et al. Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk Lymphoma 2004; 45: 2085–2092
   PubMed Web of Science ®Google Scholar
• Viviani S, Notti P, Bonfante V, et al. Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience. Med Oncol 2000; 17: 59–63
   PubMed Web of Science ®Google Scholar
• Gorschluter M, Bohlen H, Hasenclever D, Diehl V, Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol 1995; 6: 477–482
   PubMed Web of Science ®Google Scholar
• Gruss H J, Dolken G, Brach M A, Mertelsmann R, Herrmann F. The significance of serum levels of soluble 60kDa receptors for tumor necrosis factor in patients with Hodgkin's disease. Leukemia 1993; 7: 1339–1343
   PubMed Web of Science ®Google Scholar
• Trumper L, Jung W, Dahl G, et al. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease. Ann Oncol 1994; 5(Suppl 1)93–96
   PubMedGoogle Scholar
• Vener C, Guffanti A, Pomati M, et al. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis. Leuk Lymphoma 2000; 37: 333–339
   PubMed Web of Science ®Google Scholar
• Warzocha K, Bienvenu J, Ribeiro P, et al. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer 1998; 77: 2357–2362
   PubMed Web of Science ®Google Scholar
• Clodi K, Younes A. Reed-Sternberg cells and the TNF family of receptors/ligands. Leuk Lymphoma 1997; 27: 195–205
   PubMed Web of Science ®Google Scholar
• Oki Y, Georgakis G V, Migone T S, Kwak L W, Younes A. Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica 2007; 92: 269–270
   PubMed Web of Science ®Google Scholar
• Tecchio C, Nadali G, Scapini P, et al. High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. Br J Haematol 2007; 137: 553–559
   PubMed Web of Science ®Google Scholar
• Peh S C, Kim L H, Poppema S. TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma. Am J Surg Pathol 2001; 25: 925–929
   PubMed Web of Science ®Google Scholar
• van den Berg A., Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999; 154: 1685–1691
   PubMed Web of Science ®Google Scholar
• Ma Y, Visser L, Roelofsen H, et al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood 2008; 111: 2339–2346
   PubMed Web of Science ®Google Scholar
• Niens M, Visser L, Nolte I M, et al. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol 2008; 140: 527–536
   PubMed Web of Science ®Google Scholar
• Weihrauch M R, Manzke O, Beyer M, et al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res 2005; 65: 5516–5519
   PubMed Web of Science ®Google Scholar
• Cordano P, Lake A, Shield L, et al. Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma. Br J Haematol 2005; 128: 493–495
   PubMed Web of Science ®Google Scholar
• Cozen W, Gill P S, Ingles S A, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 2004; 103: 3216–3221
   PubMed Web of Science ®Google Scholar
• Cozen W, Gill P S, Salam M T, et al. Interleukin-2, interleukin-12 and interferon-{gamma} levels and risk of young adult Hodgkin lymphoma. Blood 2008; 111: 3377–3382
   PubMed Web of Science ®Google Scholar
• da Silva G N, Bacchi M M, Rainho C A, de Oliveira D E. Epstein-Barr virus infection and single nucleotide polymorphisms in the promoter region of interleukin 10 gene in patients with Hodgkin lymphoma. Arch Pathol Lab Med 2007; 131: 1691–1696
   PubMed Web of Science ®Google Scholar
• Hohaus S, Giachelia M, Di Febo A, et al. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 2007; 18: 1376–1381
   PubMed Web of Science ®Google Scholar
• Kelly K M, Perentesis J P. Polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications. Ann Oncol 2002; 13(Suppl 1)34–39
   PubMed Web of Science ®Google Scholar
• Knecht H, Bachmann E, Joske D J, et al. Molecular analysis of the LMP (latent membrane protein) oncogene in Hodgkin's disease. Leukemia 1993; 7: 580–585
   PubMed Web of Science ®Google Scholar
• Lin J C, Lin S C, Luppi M, Torelli G, Mar E C. Geographic sequence variation of latent membrane protein 1 gene of Epstein-Barr virus in Hodgkin's lymphomas. J Med Virol 1995; 45: 183–191
   PubMed Web of Science ®Google Scholar
• Niens M, Jarrett R F, Hepkema B, et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV + Hodgkin lymphoma. Blood 2007; 110: 3310–3315
   PubMed Web of Science ®Google Scholar
• Niens M, van den B A, Diepstra A, et al. The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. Cancer Epidemiol Biomarkers Prev 2006; 15: 2280–2284
   PubMed Web of Science ®Google Scholar
• Wihlborg C, Sjoberg J, Intaglietta M, et al. Tumour necrosis factor-alpha cytokine promoter gene polymorphism in Hodgkin's disease and chronic lymphocytic leukaemia. Br J Haematol 1999; 104: 346–349
   PubMed Web of Science ®Google Scholar
• Worrillow L, Smith A, Scott K, et al. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. J Med Genet 2008; 45: 142–146
   PubMed Web of Science ®Google Scholar
• Zhou X G, Sandvej K, Li P J, et al. Epstein-Barr virus gene polymorphisms in Chinese Hodgkin's disease cases and healthy donors: identification of three distinct virus variants. J Gen Virol 2001; 82: 1157–1167
   PubMed Web of Science ®Google Scholar
• Hohaus S, Di Ruscio A, Di Febo A, et al. Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res 2005; 11: 2175–2179
   PubMed Web of Science ®Google Scholar
• Brink A A, Oudejans J J, van den Brule A J, et al. Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance?. Mod Pathol 1998; 11: 376–383
   PubMed Web of Science ®Google Scholar
• Jakovic L R, Mihaljevic B S, Jovanovic M D, et al. The expression of Ki-67 and Bcl-2 in Hodgkin's lymphoma: correlation with the International Prognostic Score and bulky disease: a study by the Serbian Lymphoma Study Group (SLG). Med Oncol 2007; 24: 45–53
   PubMed Web of Science ®Google Scholar
• Montalban C, Garcia J F, Abraira V, et al. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol 2004; 22: 1664–1673
   PubMed Web of Science ®Google Scholar
• Rassidakis G Z, Medeiros L J, McDonnell T J, et al. BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Clin Cancer Res 2002; 8: 488–493
   PubMed Web of Science ®Google Scholar
• Rassidakis G Z, Medeiros L J, Vassilakopoulos T P, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002; 100: 3935–3941
   PubMed Web of Science ®Google Scholar
• Smolewski P, Robak T, Krykowski E, et al. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res 2000; 6: 1150–1160
   PubMed Web of Science ®Google Scholar
• Vassallo J, Metze K, Traina F, de Souza C A, Lorand-Metze I. The prognostic relevance of apoptosis-related proteins in classical Hodgkin's lymphomas. Leuk Lymphoma 2003; 44: 483–488
   PubMed Web of Science ®Google Scholar
• Sanchez-Aguilera A, Montalban C, de la C P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006; 108: 662–668
   PubMed Web of Science ®Google Scholar
• Provencio M, Corbacho C, Salas C, et al. The topoisomerase IIalpha expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin Cancer Res 2003; 9: 1406–1411
   PubMed Web of Science ®Google Scholar
• Hsi E D, Sup S J, Alemany C, et al. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol 2006; 125: 776–782
   PubMed Web of Science ®Google Scholar
• Portlock C S, Donnelly G B, Qin J, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol 2004; 125: 701–708
   PubMed Web of Science ®Google Scholar
• Tzankov A, Krugmann J, Fend F, et al. Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases. Clin Cancer Res 2003; 9: 1381–1386
   PubMed Web of Science ®Google Scholar
• Valsami S, Pappa V, Rontogianni D, et al. A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4. Haematologica 2007; 92: 1343–1350
   PubMed Web of Science ®Google Scholar
• Alvaro-Naranjo T, Lejeune M, Salvado-Usach M T, et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma 2005; 46: 1581–1591
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado M T, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11: 1467–1473
   PubMed Web of Science ®Google Scholar
• Asano N, Oshiro A, Matsuo K, et al. Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study. J Clin Oncol 2006; 24: 4626–4633
   PubMed Web of Science ®Google Scholar
• Baur A S, Meuge-Moraw C, Michel G, Delacretaz F. Prognostic value of follicular dendritic cells in nodular sclerosing Hodgkin's disease. Histopathology 1998; 32: 512–520
   PubMed Web of Science ®Google Scholar
• Camilleri-Broet S, Ferme C, Berger F, et al. TiA1 in advanced-stage classical Hodgkin's lymphoma: no prognostic impact for positive tumour cells or number of cytotoxic cells. Virchows Arch 2004; 445: 344–346
   PubMed Web of Science ®Google Scholar
• Diepstra A, van Imhoff G W, Karim-Kos H E, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007; 25: 3101–3108
   PubMed Web of Science ®Google Scholar
• Molin D, Edstrom A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 2002; 119: 122–124
   PubMed Web of Science ®Google Scholar
• Oudejans J J, Jiwa N M, Kummer J A, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997; 89: 1376–1382
   PubMed Web of Science ®Google Scholar
• Kelley T W, Pohlman B, Elson P, Hsi E D. The ratio of FOXP3 + regulatory T cells to granzyme B + cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007; 128: 958–965
   PubMed Web of Science ®Google Scholar
• Morente M M, Piris M A, Abraira V, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood 1997; 90: 2429–2436
   PubMed Web of Science ®Google Scholar
• Spector N, Milito C B, Biasoli I, et al. The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma. Leuk Lymphoma 2005; 46: 1301–1306
   PubMed Web of Science ®Google Scholar
• Xerri L, Bouabdallah R, Camerlo J, Hassoun J. Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data. Hum Pathol 1994; 25: 449–454
   PubMed Web of Science ®Google Scholar
• Smolewski P, Niewiadomska H, Los E, Robak T. Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells; clinical and pathological implications in patients with Hodgkin's disease. Int J Oncol 2000; 17: 603–609
   PubMed Web of Science ®Google Scholar
• Benharroch D, Levy A, Prinsloo I, et al. Apoptotic index as a prognostic factor in Hodgkin's disease. Leuk Lymphoma 1999; 33: 351–359
   PubMed Web of Science ®Google Scholar
• Dukers D F, Meijer C J, ten Berge R L, et al. High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome. Blood 2002; 100: 36–42
   PubMed Web of Science ®Google Scholar
• Smolewski P, Niewiadomska H, Blonski J Z, Robak T, Krykowski E. Expression of proliferating cell nuclear antigen (PCNA) and p53, bcl-2 or C-erb B-2 proteins on Reed-Sternberg cells: prognostic significance in Hodgkin's disease. Neoplasma 1998; 45: 140–147
   PubMed Web of Science ®Google Scholar
• Garcia J F, Camacho F I, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003; 101: 681–689
   PubMed Web of Science ®Google Scholar
• Savage K J, Monti S, Kutok J L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871–3879
   PubMed Web of Science ®Google Scholar
• Alonso M A, Millan J. The role of lipid rafts in signalling and membrane trafficking in T lymphocytes. J Cell Sci 2001; 114: 3957–3965
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Plonquet A, Alonso M A, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol 2002; 15: 1172–1180
   PubMed Web of Science ®Google Scholar